NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler (SYMCO)
This study has been completed.
Sponsor:
AstraZeneca
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00557297
First received: November 9, 2007
Last updated: September 24, 2008
Last verified: September 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this non-interventional study is to ensure that patients in routine clinical practice follow given treatment instructions and to evaluate the number of reliever inhalations as well as the number of patient/days with more than 8/12 total inhalations at any day. If the number of reliever inhalations and thus the received inhaled glucocorticosteroid dose is not excessive, the safety conclusions from the clinical studies can be extrapolated to real life for better acceptance of SMART (Symbicort Maintenance and Reliever Therapy).
| Condition |
|---|
|
Asthma |
| Study Type: | Observational |
| Study Design: | Time Perspective: Cross-Sectional |
| Official Title: | NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler |
Resource links provided by NLM:
Further study details as provided by AstraZeneca:
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Persistent asthma
- Prior Symbicort Turbuhaler maintenance and reliever therapy in a single inhaler
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00557297
Locations
| Latvia | |
| Research Site | |
| Aluksne, Latvia | |
| Research Site | |
| Aozkraukle, Latvia | |
| Research Site | |
| Balvi, Latvia | |
| Research Site | |
| Cesis, Latvia | |
| Research Site | |
| Gulbene, Latvia | |
| Research Site | |
| Jekabpils, Latvia | |
| Research Site | |
| Jumprava, Latvia | |
| Research Site | |
| Kekava, Latvia | |
| Research Site | |
| Kraslava, Latvia | |
| Research Site | |
| Kuldiga, Latvia | |
| Research Site | |
| Liepaja, Latvia | |
| Research Site | |
| Limbazi, Latvia | |
| Research Site | |
| Livani, Latvia | |
| Research Site | |
| Madona, Latvia | |
| Research Site | |
| Ogre, Latvia | |
| Research Site | |
| Preili, Latvia | |
| Research Site | |
| Rezekne, Latvia | |
| Research Site | |
| Salacgriva, Latvia | |
| Research Site | |
| Saldus, Latvia | |
| Research Site | |
| Talsi, Latvia | |
| Research Site | |
| Valniera, Latvia | |
| Research Site | |
| Ventspils, Latvia | |
Sponsors and Collaborators
AstraZeneca
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00557297 History of Changes |
| Other Study ID Numbers: | D5890L00031 |
| Study First Received: | November 9, 2007 |
| Last Updated: | September 24, 2008 |
| Health Authority: | Latvia: State Agency of Medicines |
Keywords provided by AstraZeneca:
|
asthma SMART inhaled glucocorticosteroid |
reliever maintenance single inhaler |
Additional relevant MeSH terms:
|
Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases Symbicort Budesonide Anti-Asthmatic Agents |
Respiratory System Agents Therapeutic Uses Pharmacologic Actions Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Inflammatory Agents |
ClinicalTrials.gov processed this record on May 22, 2013